INmune Bio向Nature Portfolio Journal，npj Dementia提交了2期MINDFuL试验的详细结果

INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces the submission of a manuscript detailing the results of its Phase 2 MINDFuL trial. The manuscript, titled, "XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer's Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial," has been submitted for peer review to npj Dementia, a Nature Portfolio journal.